deltatrials
Completed PHASE3 NCT00264914

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Sponsor: Sanofi

Conditions Hyponatremia Inappropriate ADH Syndrome
Interventions SR121463B
Updated 7 times since 2017 Last updated: Jan 19, 2009 Started: Jul 31, 2005 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

Listed as NCT00264914, this PHASE3 trial focuses on Hyponatremia and Inappropriate ADH Syndrome and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany, Bridgewater, United States, Budapest, Hungary, Causeway Bay, Hong Kong, Diegem, Belgium, Geneva, Switzerland, Laval, Canada, Macquarie Park, Australia, Moscow, Russia, Paris, France and 1 more location